BioSpace News Archive

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2022 and provided corporate updates.

Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) today provided a business update and reported financial results for the fiscal 2023 third quarter ended January 31, 2023.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the full year ended December 31, 2022 and provided a business update.

Escient Pharmaceuticals announced the presentation of preclinical data in a mouse model of atopic dermatitis related to the company’s EP262 development program at the American Academy of Dermatology annual meeting being held in New Orleans, Louisiana, March 17-21, 2023.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) today announced that at its late cycle meeting for the SRP-9001 (delandistrogene moxeparvovec) biologics license application (BLA), the U.S. Food and Drug Administration’s Office of Therapeutics (OTP) has determined that an advisory committee meeting will be held for SRP-9001 in advance of the May 29, 2023 regulatory action date.

Edesa Biotech, Inc. announced that the company has been selected to present clinical trial data from a Phase 2B multi-dose study of its EB01 drug candidate at a Late Breaking Abstract session of the American Academy of Dermatology Association annual meeting being held March 17-21, 2023.

2seventy bio, Inc. reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2022.

Adamis Pharmaceuticals Corporation announced financial results for the full year ended December 31, 2022, and provided an update on recent corporate developments.

Lifecore Biomedical, Inc. announced that it has entered into a term sheet to seek to expand its existing CDMO relationship with one of its long-term commercial Hyaluronic Acid and CDMO customers, including obtaining certain up-front cash payments and capital reimbursement obligations from the customer and entering into a non-binding agreement to amend the current contract manufacturing agreement with the customer to extend and expand the existing relationship.

Century Therapeutics, Inc. today reported financial results and business highlights for the full-year ended December 31, 2022.